Marjo van Kasteren
Radboud University Nijmegen Medical Centre
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marjo van Kasteren.
Clinical Infectious Diseases | 2007
Marjo van Kasteren; Judith Manniën; Alewijn Ott; Bart Jan Kullberg; Annette S. de Boer; Inge C. Gyssens
BACKGROUND Surgical site infections (SSIs) following total hip arthroplasty can lead to prolonged hospitalization, increased morbidity and mortality, and high costs. This article analyzes the effect of various parameters of surgical antibiotic prophylaxis on the risk of SSI following total hip arthroplasty. METHODS Data about SSI and potential prophylaxis-, patient-, and procedure-related risk factors were prospectively collected for 1922 patients who underwent elective total hip arthroplasty in 11 hospitals that participated in the Dutch intervention project, Surgical Prophylaxis and Surveillance. Multivariate logistic regression analysis was performed to correct for random variation among hospitals. RESULTS SSIs (superficial and deep) occurred in 50 patients (2.6%). The highest odds ratios for SSI were found in patients who received prophylaxis after incision (2.8, 95% confidence interval [CI], 0.9-8.6; P=.07), had an American Society of Anesthesiology score that was >2 (2.8, 95% CI, 0.8-9.2; P=.09), and experienced a duration of surgery that was >75th percentile (2.5; 95% CI, 1.1-5.8; P=.04). Prolonged prophylaxis after the end of surgery and the use of antibiotic-impregnated cement did not contribute to fewer SSIs in this study. CONCLUSIONS This study suggests that intervention programs in search of amendable factors to prevent SSI should focus on timely administration of antibiotic prophylaxis.
Clinical Infectious Diseases | 2016
L. Marije Hofstra; Nicolas Sauvageot; Jan Albert; Ivailo Alexiev; Federico García; Daniel Struck; David A. M. C. van de Vijver; Birgitta Åsjö; Danail Beshkov; Suzie Coughlan; Diane Descamps; Algirdas Griskevicius; Osamah Hamouda; Andrzej Horban; Marjo van Kasteren; Tatjana Kolupajeva; Leondios G. Kostrikis; Kirsi Liitsola; Marek Linka; Orna Mor; Claus Nielsen; Dan Otelea; Dimitrios Paraskevis; Roger Paredes; Mario Poljak; Elisabeth Puchhammer-Stöckl; Anders Sönnerborg; Danica Stanekova; Maja Stanojevic; Kristel Van Laethem
Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.
Infection Control and Hospital Epidemiology | 2006
Judith Manniën; Marjo van Kasteren; Nico Nagelkerke; Inge C. Gyssens; Bart Jan Kullberg; Jan C. Wille; Annette S. de Boer
OBJECTIVE To compare the rate of surgical site infection (SSI) before and after an intervention period in which an optimized policy for antibiotic prophylaxis was implemented. To demonstrate that a more prudent, restrictive policy would not have a detrimental effect on patient outcomes. DESIGN Before-after trial with prospective SSI surveillance in the Dutch nosocomial surveillance network (Preventie Ziekenhuisinfecties door Surveillance [PREZIES]), using the criteria of the Centers for Disease Control, including postdischarge surveillance for up to 1 year. METHODS During a preintervention period and a postintervention period (both 6-13 months), 12 Dutch hospitals collected data on antimicrobial prophylaxis and SSI rates. The study was limited to commonly performed surgical procedures in 4 specialties: vascular, intestinal, gynecological and orthopedic surgery. Selected risk factors for analysis were sex, age, American Society of Anesthesiologists classification, wound contamination class, duration of surgery, length of hospital stay before surgery, and urgency of surgery (elective or acute). RESULTS A total of 3,621 procedures were included in the study, of which 1,668 were performed before the intervention and 1,953 after. The overall SSI rate decreased from 5.4% to 4.5% (P=.22). Among the procedures included in the study, the largest proportion (55%) were total hip arthroplasty, and the smallest proportion (2%) were replacement of the head of the femur. SSI rates varied from 0% for vaginal hysterectomy to 21.1% for femoropopliteal or femorotibial bypass surgery. Crude and adjusted odds ratios showed that there were no significant changes in procedure-specific SSI rates after the intervention (P>.1). CONCLUSIONS An optimized and restrictive antibiotic prophylaxis policy had no detrimental effect on the outcome of clean and clean contaminated surgery, as measured by SSI rate.
Clinical and Vaccine Immunology | 2012
Linda M. Kampschreur; Jan Jelrik Oosterheert; Annemarie M. C. Koop; M. C. A. Wegdam-Blans; Corine E. Delsing; Chantal P. Bleeker-Rovers; Monique G.L. de Jager-Leclercq; Cornelis A. R. Groot; Tom Sprong; Marrigje H. Nabuurs-Franssen; Nicole H. M. Renders; Marjo van Kasteren; Yvonne Soethoudt; Sybrandus N. Blank; Marjolijn J. H. Pronk; Rolf H.H. Groenwold; Andy I. M. Hoepelman; Peter C. Wever
ABSTRACT Diagnosis of chronic Q fever is difficult. PCR and culture lack sensitivity; hence, diagnosis relies mainly on serologic tests using an immunofluorescence assay (IFA). Optimal phase I IgG cutoff titers are debated but are estimated to be between 1:800 and 1:1,600. In patients with proven, probable, or possible chronic Q fever, we studied phase I IgG antibody titers at the time of positive blood PCR, at diagnosis, and at peak levels during chronic Q fever. We evaluated 200 patients, of whom 93 (46.5%) had proven, 51 (25.5%) had probable, and 56 (28.0%) had possible chronic Q fever. Sixty-five percent of proven cases had positive Coxiella burnetii PCR results for blood, which was associated with high phase I IgG. Median phase I IgG titers at diagnosis and peak titers in patients with proven chronic Q fever were significantly higher than those for patients with probable and possible chronic Q fever. The positive predictive values for proven chronic Q fever, compared to possible chronic Q fever, at titers 1:1,024, 1:2,048, 1:4,096, and ≥1:8,192 were 62.2%, 66.7%, 76.5%, and ≥86.2%, respectively. However, sensitivity dropped to <60% when cutoff titers of ≥1:8,192 were used. Although our study demonstrated a strong association between high phase I IgG titers and proven chronic Q fever, increasing the current diagnostic phase I IgG cutoff to >1:1,024 is not recommended due to increased false-negative findings (sensitivity < 60%) and the high morbidity and mortality of untreated chronic Q fever. Our study emphasizes that serologic results are not diagnostic on their own but should always be interpreted in combination with clinical parameters.
Clinical Infectious Diseases | 2018
Anne Boerekamps; Guido E.L. van den Berk; Lauw N Fanny; Eliane M. S. Leyten; Marjo van Kasteren; Arne van Eeden; D. Posthouwer; Mark A.A. Claassen; Anton S Dofferhoff; Dominique W M Verhagen; Wouter F. W. Bierman; Kamilla D. Lettinga; Frank P. Kroon; Corine E. Delsing; Paul H. P. Groeneveld; Robert Soetekouw; Edgar J.G. Peters; Sebastiaan J. Hullegie; Stephanie Popping; David A. M. C. van de Vijver; Charles A. Boucher; Joop E. Arends; Bart J. A. Rijnders
Background Direct-acting antivirals (DAAa) cure hepatitis C virus (HCV) infections in 95% of infected patients. Modeling studies predict that universal HCV treatment will lead to a decrease in the incidence of new infections but real-life data are lacking. The incidence of HCV among Dutch human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) has been high for >10 years. In 2015 DAAs became available to all Dutch HCV patients and resulted in a rapid treatment uptake in HIV-positive MSM. We assessed whether this uptake was followed by a decrease in the incidence of HCV infections. Methods Two prospective studies of treatment for acute HCV infection enrolled patients in 17 Dutch HIV centers, having 76% of the total HIV-positive MSM population in care in the Netherlands. Patients were recruited in 2014 and 2016, the years before and after unrestricted DAA availability. We compared the HCV incidence in both years. Results The incidence of acute HCV infection decreased from 93 infections during 8290 person-years of follow-up (PYFU) in 2014 (11.2/1000 PYFU; 95% confidence interval [CI], 9.1-13.7) to 49 during 8961 PYFU in 2016 (5.5/1000 PYFU; 4.1-7.2). The incidence rate ratio of 2016 compared with 2014 was 0.49 (95% CI, .35-.69). Simultaneously, a significant increase in the percentage positive syphilis (+2.2%) and gonorrhea (+2.8%) tests in HIV-positive MSM was observed at sexual health clinics across the Netherlands and contradicts a decrease in risk behavior as an alternative explanation. Conclusions Unrestricted DAA availability in the Netherlands was followed by a 51% decrease in acute HCV infections among HIV-positive MSM.
Frontiers in Pharmacology | 2016
Nikki Mulligan; Stein Schalkwijk; Brookie M. Best; Angela Colbers; Jiajia Wang; Edmund V. Capparelli; José Moltó; Alice Stek; Graham Taylor; Elizabeth Smith; Carmen Hidalgo Tenorio; Nahida Chakhtoura; Marjo van Kasteren; Courtney V. Fletcher; Mark Mirochnick; David M. Burger
Background: The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women. Methods: IMPAACT P1026s and PANNA are on-going, non-randomized, open-label, parallel-group, multi-center phase-IV prospective studies in HIV-infected pregnant women. Intensive steady-state 12-h pharmacokinetic profiles were performed from 2nd trimester through postpartum. Etravirine was measured at two labs using validated ultra performance liquid chromatography (detection limits: 0.020 and 0.026 mcg/mL). Results: Fifteen women took etravirine 200 mg twice-daily. Etravirine AUC0–12 was higher in the 3rd trimester compared to paired postpartum data by 34% (median 8.3 vs. 5.3 mcg*h/mL, p = 0.068). Etravirine apparent oral clearance was significantly lower in the 3rd trimester of pregnancy compared to paired postpartum data by 52% (median 24 vs. 38 L/h, p = 0.025). The median ratio of cord blood to maternal plasma concentration at delivery was 0.52 (range: 0.19–4.25) and no perinatal transmission occurred. Conclusion: Etravirine apparent oral clearance is reduced and exposure increased during the third trimester of pregnancy. Based on prior dose-ranging and safety data, no dose adjustment is necessary for maternal health but the effects of etravirine in utero are unknown. Maternal health and infant outcomes should be closely monitored until further infant safety data are available. Clinical Trial registration: The IMPAACT protocol P1026s and PANNA study are registered at ClinicalTrials.gov under NCT00042289 and NCT00825929.
The Journal of Nuclear Medicine | 2018
Ilse J.E. Kouijzer; Linda M. Kampschreur; Peter C. Wever; Corneline J. Hoekstra; Marjo van Kasteren; Monique G.L. de Jager-Leclercq; Marrigje H. Nabuurs-Franssen; M. C. A. Wegdam-Blans; Heidi S.M. Ammerlaan; Jacqueline Buijs; Lioe Fee De Geus-Oei; Wim J.G. Oyen; Chantal P. Bleeker-Rovers
In 1%–5% of all acute Q fever infections, chronic Q fever develops, mostly manifesting as endocarditis, infected aneurysms, or infected vascular prostheses. In this study, we investigated the diagnostic value of 18F-FDG PET/CT in chronic Q fever at diagnosis and during follow-up. Methods: All adult Dutch patients suspected of chronic Q fever who were diagnosed since 2007 were retrospectively included until March 2015, when at least one 18F-FDG PET/CT scan was obtained. Clinical data and results from 18F-FDG PET/CT at diagnosis and during follow-up were collected. 18F-FDG PET/CT scans were prospectively reevaluated by 3 nuclear medicine physicians using a structured scoring system. Results: In total, 273 patients with possible, probable, or proven chronic Q fever were included. Of all 18F-FDG PET/CT scans performed at diagnosis, 13.5% led to a change in diagnosis. Q fever–related mortality rate in patients with and without vascular infection based on 18F-FDG PET/CT was 23.8% and 2.1%, respectively (P = 0.001). When 18F-FDG PET/CT was added as a major criterion to the modified Duke criteria, 17 patients (1.9-fold increase) had definite endocarditis. At diagnosis, 19.6% of 18F-FDG PET/CT scans led to treatment modification. During follow-up, 57.3% of 18F-FDG PET/CT scans resulted in treatment modification. Conclusion: 18F-FDG PET/CT is a valuable technique in diagnosis of chronic Q fever and during follow-up, often leading to a change in diagnosis or treatment modification and providing important prognostic information on patient survival.
Clinical Infectious Diseases | 2015
Angela Colbers; Brookie M. Best; Stein Schalkwijk; Jiajia Wang; Alice Stek; Carmen Hidalgo Tenorio; David Hawkins; Graham Taylor; Regis Kreitchmann; Sandra K. Burchett; Annette Haberl; Kabamba Kabeya; Marjo van Kasteren; Elizabeth Smith; Edmund V. Capparelli; David M. Burger; Mark Mirochnick; M.E. van der Ende; Mc Erasmus; A.J.A.M. van der Ven; Jeannine F. J. B. Nellen; José Moltó; E. Nicastri; Carlo Giaquinto; Andrea Gingelmaier; F. Lyons; John S. Lambert; Christoph Wyen; Gerd Faetkenheuer; Jürgen K. Rockstroh
OBJECTIVE To describe the pharmacokinetics of maraviroc in human immunodeficiency virus (HIV)-infected women during pregnancy and post partum. METHODS HIV-infected pregnant women receiving maraviroc as part of clinical care had intensive steady-state 12-hour pharmacokinetic profiles performed during the third trimester and ≥2 weeks after delivery. Cord blood samples and matching maternal blood samples were taken at delivery. The data were collected in 2 studies: P1026 (United States) and PANNA (Europe). Pharmacokinetic parameters were calculated. RESULTS Eighteen women were included in the analysis. Most women (12; 67%) received 150 mg of maraviroc twice daily with a protease inhibitor, 2 (11%) received 300 mg twice daily without a protease inhibitor, and 4 (22%) had an alternative regimen. The geometric mean ratios for third-trimester versus postpartum maraviroc were 0.72 (90% confidence interval, .60-.88) for the area under the curve over a dosing interval (AUCtau) and 0.70 (0.58-0.85) for the maximum maraviroc concentration. Only 1 patient showed a trough concentration (Ctrough) below the suggested target of 50 ng/mL, both during pregnancy and post partum. The median ratio of maraviroc cord blood to maternal blood was 0.33 (range, 0.03-0.56). The viral load close to delivery was <50 copies/mL in 13 women (76%). All children were HIV negative at testing. CONCLUSIONS Overall maraviroc exposure during pregnancy was decreased, with a reduction in AUCtau and maximum concentration of about 30%. Ctrough was reduced by 15% but exceeded the minimum Ctrough target concentration. Therefore, the standard adult dose seems sufficient in pregnancy. CLINICAL TRIALS REGISTRATION NCT00825929 and NCT000422890.
Journal of Antimicrobial Chemotherapy | 2005
Marjo van Kasteren; Judith Manniën; Bart Jan Kullberg; Annette S. de Boer; Nico Nagelkerke; Marja Ridderhof; Jan C. Wille; Inge C. Gyssens
JAMA Internal Medicine | 2004
Nils P. J. Vogtländer; Marjo van Kasteren; Stephanie Natsch; Bart Jan Kullberg; Y.A. Hekster; Jos W. M. van der Meer